Back to top
more

BioSpecifics Technologies Corp (BSTC)

(Delayed Data from NSDQ)

$66.72 USD

66.72
62,398

+0.21 (0.32%)

Updated May 3, 2019 04:00 PM ET

After-Market: $66.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

Nalak Das headshot

Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

The U.S. labor market is the major driver of the bull run, which is more than a decade old.

Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

3 Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock

BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Nalak Das headshot

5 Stocks With Recent Price Strength Despite Market Volatility

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK

Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK

Tirthankar Chakraborty headshot

4 Top Stocks to Buy for Superb Earnings Growth

We highlight stocks that have striking earnings growth and positive estimate revisions.

BioSpecifics (BSTC) Upgraded to Strong Buy: Here's What You Should Know

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.

BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?

Is (BSTC) Outperforming Other Medical Stocks This Year?

Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.

Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?

Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

Verrica (VRCA) Catches Eye: Stock Jumps 6.9%

Verrica (VRCA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study

Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.

Flexion Starts Phase III Enrollment on Zilretta for Hip OA

Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.

Portola Up as Large-Scale Andexxa Production Gets FDA Nod

Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.

Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis

Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.

Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?

Is (BSTC) Outperforming Other Medical Stocks This Year?